Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
- To compare to control (Group A) (peginterferon alfa-2a [Peg IFN-a-2a] and ribavirin [RBV] for 48 weeks) the proportion of subjects who achieve sustained viral response (SVR, undetectable HCV RNA 24 weeks after completion of treatment) when given telaprevir in combination with: Peg IFN-a-2a and RBV for 24 weeks followed by 24 weeks of Peg IFN a-2a and RBV given alone (Group B); Peg IFN-a-2a for 24 weeks (Group C); Peg IFN-a-2a and RBV for 12 weeks followed by 12 weeks of Peg IFN-a-2a and RBV given alone (Group D).
Critère d'inclusion
- Hepatitis C virus (HCV) infection